908 related articles for article (PubMed ID: 18184959)
1. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.
Davies DM; Johnson SR; Tattersfield AE; Kingswood JC; Cox JA; McCartney DL; Doyle T; Elmslie F; Saggar A; de Vries PJ; Sampson JR
N Engl J Med; 2008 Jan; 358(2):200-3. PubMed ID: 18184971
[No Abstract] [Full Text] [Related]
3. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.
Davies DM; de Vries PJ; Johnson SR; McCartney DL; Cox JA; Serra AL; Watson PC; Howe CJ; Doyle T; Pointon K; Cross JJ; Tattersfield AE; Kingswood JC; Sampson JR
Clin Cancer Res; 2011 Jun; 17(12):4071-81. PubMed ID: 21525172
[TBL] [Abstract][Full Text] [Related]
4. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial.
Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y
Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809
[TBL] [Abstract][Full Text] [Related]
5. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K
Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of sirolimus in treating tuberous sclerosis and lymphangioleiomyomatosis.
Paul E; Thiele E
N Engl J Med; 2008 Jan; 358(2):190-2. PubMed ID: 18184966
[No Abstract] [Full Text] [Related]
7. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sirolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: a systematic review.
Peng ZF; Yang L; Wang TT; Han P; Liu ZH; Wei Q
J Urol; 2014 Nov; 192(5):1424-30. PubMed ID: 24813310
[TBL] [Abstract][Full Text] [Related]
9. Lymphangioleiomyomatosis.
Johnson SR; Taveira-DaSilva AM; Moss J
Clin Chest Med; 2016 Sep; 37(3):389-403. PubMed ID: 27514586
[TBL] [Abstract][Full Text] [Related]
10. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
Johnson J; Somerfield W; Johnson SR
Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
[TBL] [Abstract][Full Text] [Related]
11. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Berkowitz N; Miao S; Segal S; Peyrard S; Budde K
Nephrol Dial Transplant; 2016 Jan; 31(1):111-9. PubMed ID: 26156073
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin and rapalogs for tuberous sclerosis complex.
Sasongko TH; Ismail NF; Zabidi-Hussin Z
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709
[TBL] [Abstract][Full Text] [Related]
13. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex.
Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y
Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282
[TBL] [Abstract][Full Text] [Related]
14. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.
Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Belousova E; Frost MD; Sauter M; Brakemeier S; de Vries PJ; Berkowitz N; Voi M; Peyrard S; Budde K
PLoS One; 2017; 12(8):e0180939. PubMed ID: 28792952
[TBL] [Abstract][Full Text] [Related]
15. The effect of sirolimus on angiomyolipoma is determined by decrease of fat-poor compartments and includes striking reduction of vascular structures.
Watanabe EH; Coelho FMA; Filho HL; Balbo BEP; Neves PDMM; Franzin FM; Yamauchi FI; Onuchic LF
Sci Rep; 2021 Apr; 11(1):8493. PubMed ID: 33875750
[TBL] [Abstract][Full Text] [Related]
16. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
Robb VA; Astrinidis A; Henske EP
Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
[TBL] [Abstract][Full Text] [Related]
17. mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex.
Franz DN; Krueger DA
Am J Med Genet C Semin Med Genet; 2018 Sep; 178(3):365-373. PubMed ID: 30307123
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
Yu J; Parkhitko AA; Henske EP
Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
[TBL] [Abstract][Full Text] [Related]
19. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
[TBL] [Abstract][Full Text] [Related]
20. Conservative management of pulmonary lymphangioleiomyomatosis and tuberous sclerosis complicated by renal angiomyolipomas in pregnancy.
Cleary-Goldman J; Sanghvi AV; Nakhuda GS; Robinson JN
J Matern Fetal Neonatal Med; 2004 Feb; 15(2):132-4. PubMed ID: 15209123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]